What the SURPASS Tirzepatide Programme Tells You Before You Decide

What the SURPASS Programme Was Actually Designed to Measure

The name SURPASS covers a family of randomised controlled trials, not a single experiment. Each trial tested tirzepatide head-to-head against a different standard treatment (placebo, insulin degludec, insulin glargine, semaglutide 1mg, and others) in adults with type 2 diabetes who weren't achieving adequate blood sugar control. The core outcomes were HbA1c reduction (a marker of average blood glucose over roughly three months) and change in body weight.

Across the programme, tirzepatide at all three maintenance doses produced consistent, statistically significant reductions in both measures. The 15mg dose routinely produced the largest effects, with a meaningful proportion of trial participants reaching an HbA1c below the diagnostic threshold for diabetes. Weight loss was a secondary outcome in SURPASS, clinically relevant, but not the primary lens. That distinction matters when you're researching tirzepatide specifically for weight management, because the weight-focused SURPASS trial data sits alongside a separate programme entirely.

You can read the full results of individual SURPASS studies, including SURPASS-1, via our dedicated SURPASS-1 overview page. Results from SURPASS-3, which compared tirzepatide directly against insulin degludec, are covered in detail on our dedicated page. The trial design and findings are also indexed through PubMed if you want the primary papers.

SURPASS Versus SURMOUNT: Why the Distinction Matters for You

A common source of confusion is conflating SURPASS (diabetes trials) with SURMOUNT (weight-management trials). If your interest in tirzepatide is weight loss rather than diabetes management, the SURMOUNT programme is the directly relevant evidence base. SURMOUNT-1, for example, enrolled adults with obesity or overweight and at least one weight-related condition but without type 2 diabetes, and ran for 72 weeks. Average body-weight reduction at the 15mg dose reached approximately 20–21%, as reported in the New England Journal of Medicine. The SURPASS trials, by contrast, enrolled people who already had diabetes, a different physiology, different baseline weight, different primary goal.

This isn't a technicality. It affects how you read the numbers. Weight loss in SURPASS was a secondary finding in a diabetes population; weight loss in SURMOUNT was the primary endpoint in an obesity population. Both sets of data contributed to tirzepatide's UK licences (one for type 2 diabetes, one for weight management) and together they explain why tirzepatide holds two separate indications. Understanding which evidence applies to your situation is part of what your prescriber works through with you.

For a full comparison of the individual studies within the programme, the SURPASS study breakdown covers each trial's design and headline results side by side.

The Practical Factors That Sit Alongside the Trial Data

Trial evidence tells you about averages across a large enrolled population. Your prescriber's job is to apply that evidence to one person: you. Several factors shape whether tirzepatide is the right fit, and none of them appear in a trial table.

Eligibility for the weight-management licence requires a BMI of 30 or above, or 27 or above alongside a qualifying condition such as high blood pressure, high cholesterol, obstructive sleep apnoea, or cardiovascular disease. The prescriber also considers your medication list, any relevant history, and what you're hoping treatment will help you achieve. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance, your prescriber will apply these during assessment.

Side effects in the SURPASS and SURMOUNT trials were predominantly gastrointestinal: nausea, loose stools, constipation, and indigestion featured most commonly, particularly after starting or following a dose increase. Most participants found these settled as their body adjusted. The NHS medicines page for tirzepatide sets out the full side-effect profile in plain language, and the Patient Information Leaflet supplied with your treatment covers it in detail.

Cost and access are also real considerations. The treatment options and pricing page explains what's included in a private prescription route, and our Mounjaro information page covers the UK-specific details, doses, storage, what to expect from the pen itself. When your treatment arrives, it comes via tracked DPD delivery in plain, unbranded packaging, refrigerated for the journey: nothing about the box tells a neighbour what's inside.

What Comes After the Evidence Review

The SURPASS programme gave regulators, and then NICE, the data needed to licence and recommend tirzepatide. NICE's appraisal of tirzepatide for weight management (TA1026) drew on both the diabetes and weight-focused trials when assessing the medicine's clinical profile. Reading that NICE guidance on tirzepatide (TA1026) gives you a sense of how the UK's clinical body weighed the evidence overall.

For most people, the evidence review is the first step, not the last one. A prescriber takes your full picture (health history, current medicines, BMI, goals) and maps it against that evidence. That's what a clinical consultation is for. Our prescribers at nume are GPhC-registered Independent Prescribers; a real clinician reads every submission the same day. If you're ready to move from reading to talking, start your free consultation and let that conversation take it from here.